A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors

ClinicalTrials.gov ID: NCT02715531

Public ClinicalTrials.gov record NCT02715531. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 3, 2026, 6:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Multicenter Phase Ib Study of The Safety and Efficacy of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab and/or Other Treatments in Patients With Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab in combination with bevacizumab, bevacizumab + oxaliplatin, leucovorin and 5-fluorouracil (5-FU) (FOLFOX), vanucizumab, nab-paclitaxel + gemcitabine, FOLFOX, or 5-FU + cisplatin, in participants with solid tumors.

Study identification

NCT ID: NCT02715531
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Hoffmann-La Roche; Industry
Enrollment: 243 participants

Conditions and interventions

Conditions

Solid Tumor

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 5, 2016
Primary completion: May 30, 2021
Completion: May 30, 2021
Last update posted: Jul 8, 2021

2016 – 2021

United States locations

U.S. sites: 12
U.S. states: 10
U.S. cities: 11

Facility	City	State	ZIP	Site status
Stanford Cancer Institute; Hematology	Palo Alto	California	94305	—
University of Colorado Hospital	Aurora	Colorado	80045	—
Yale School of Medicine	New Haven	Connecticut	06510	—
Georgetown University Medical Center	Washington D.C.	District of Columbia	20007	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Dana Farber Cancer Institute	Boston	Massachusetts	02215	—
Mayo Clinic	Rochester	Minnesota	55905	—
Columbia University Medical Center	New York	New York	10027	—
UNC Lineberger Comprehensive Cancer Center	Chapel Hill	North Carolina	27514	—
Duke Cancer Institute	Durham	North Carolina	27710	—
Sarah Cannon Research Inst.	Nashville	Tennessee	37203	—
Medical College of Wisconsin	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02715531, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 8, 2021 · Synced Sep 3, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02715531 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →